Stock PLEDPHARMA AB (PUBL)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

PledPharma AB (publ) Stock Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
Other stock markets
- SEK - Intraday chart for PledPharma AB (publ)
May. 03 Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 22 Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 58.49M 5.41M Sales 2025 * 496M 45.87M Capitalization 1.79B 165M
Net income 2024 * -291M -26.94M Net income 2025 * 171M 15.83M EV / Sales 2024 * 32.3 x
Net Debt 2024 * 102M 9.47M Net cash position 2025 * 119M 11.01M EV / Sales 2025 * 3.37 x
P/E ratio 2024 *
-6.81 x
P/E ratio 2025 *
9.46 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.61%
More Fundamentals * Assessed data

Latest news about PledPharma AB (publ)

Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance CI
Transcript : Egetis Therapeutics AB - Analyst/Investor Day
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA CI
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises MT
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Egetis Therapeutics' Marketing Authorization Application for Emcitate Validated in EU MT
Egetis Therapeutics AB Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency CI
Egetis Therapeutics AB Secures Combined Financing of Approximately SEK 462 Million CI
Egetis Therapeutics Raises SEK462 Million Via Private Placement, Debt Financing MT
Egetis Therapeutics Seeks Marketing Authorization for Genetic Disorder Treatment in Europe MT
Egetis Therapeutics AB Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency CI
Egetis Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Latest transcript on PledPharma AB (publ)

Logo PledPharma AB (publ)
Egetis Therapeutics AB - Analyst/Investor Day
More transcripts

Press releases PledPharma AB (publ)

Bulletin from Egetis Therapeutics’ Annual General Meeting 2024 AQ
Egetis Therapeutics Q1 2024 - EU launch closing in AQ
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ) AQ
Egetis Therapeutics' : 2023 Annual Report published PU
Egetis Therapeutics’ 2023 Annual Report published AQ
More press releases

Managers and Directors - PledPharma AB (publ)

Managers TitleAgeSince
Nicklas Westerholm CEO
 Chief Executive Officer 48 17-06-15
Yilmaz Mahshid DFI
 Director of Finance/CFO 45 17-12-30
Marianne Berrens-Peijnenburg CTO
 Chief Tech/Sci/R&D Officer - 22-05-04
Members of the board TitleAgeSince
Mats Blom BRD
 Director/Board Member 59 21-03-31
Peder Sven Walberg BRD
 Director/Board Member 50 19-12-31
Thomas Lönngren CHM
 Chairman 73 21-03-31
More insiders

Company Profile

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Sector
Biotechnology & Medical Research
Calendar
2024-05-05 - Annual General Meeting
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.88% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.68% 104B
ARGENX SE Stock argenx SE
+5.79% 22.94B
BIONTECH SE Stock BioNTech SE
-12.33% 22.34B
GENMAB A/S Stock Genmab A/S
-7.01% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.08% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.00% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.88% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.75% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. EGTX Stock
  4. Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW